Sign In
Buy CODX
$1.44
-0.120 (-7.69%)
At Close: Jul 31, 2026
Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit
09:30am, Monday, 13'th Oct 2025
SALT LAKE CITY , Oct. 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30
09:30am, Tuesday, 30'th Sep 2025
SALT LAKE CITY , Sept. 30, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
SALT LAKE CITY , Sept. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development
Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
09:47am, Wednesday, 17'th Sep 2025
SALT LAKE CITY , Sept. 17, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development
Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains
09:30am, Thursday, 11'th Sep 2025
SALT LAKE CITY , Sept. 11, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit
09:30am, Tuesday, 09'th Sep 2025
SALT LAKE CITY , Sept. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.
09:30am, Monday, 18'th Aug 2025
SALT LAKE CITY , Aug. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of
Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript
07:42pm, Thursday, 14'th Aug 2025
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2025 Earnings Conference August 14, 2025 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Brian L. Brown - CFO & Company Secretary Dwig
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Misses Revenue Estimates
06:15pm, Thursday, 14'th Aug 2025
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.25 per share a year ago.
Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results
04:01pm, Thursday, 14'th Aug 2025
SALT LAKE CITY , Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast
09:30am, Thursday, 31'st Jul 2025
SALT LAKE CITY , July 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025
09:30am, Tuesday, 15'th Jul 2025
SALT LAKE CITY , July 15, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development
Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference
09:30am, Wednesday, 14'th May 2025
Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the
Co-Diagnostics, Inc. (CODX) Q1 2025 Earnings Call Transcript
09:59pm, Thursday, 08'th May 2025
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Br
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Misses Revenue Estimates
08:10pm, Thursday, 08'th May 2025
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.31 per share a year ago.
